Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Reaches New 12-Month High - Here's What Happened

Key Points

• Shionogi & Co., Ltd. Unsponsored ADR shares reached a new 52-week high of $9.00 during trading on Tuesday, with a volume of 1,407 shares exchanged.
• The company reported $0.16 earnings per share for the last quarter, exceeding the consensus estimate of $0.14.
• Shionogi specializes in pharmaceuticals and has developed various drugs including treatments for COVID-19 and HIV, highlighting its significant role in the medical field.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $9.00 and last traded at $9.00, with a volume of 1407 shares changing hands. The stock had previously closed at $8.95.

Shionogi & Co., Ltd. Unsponsored ADR Stock Up 1.2%

The stock has a 50-day moving average of $8.57 and a two-hundred day moving average of $8.02. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.63 and a quick ratio of 6.13.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.02. The company had revenue of $672.90 million during the quarter, compared to the consensus estimate of $719.55 million. On average, equities analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 EPS for the current fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.